SRZN Profile
Surrozen, Inc. is a biotechnology company focused on discovering and developing innovative drug candidates aimed at selectively modulating the Wnt signaling pathway to promote tissue repair and regeneration. The company's proprietary technology leverages tissue-specific antibodies to address a broad spectrum of diseases affecting various organs and systems, including the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Surrozen’s pipeline features several promising candidates, notably including SZN-043 and SZN-1326. SZN-043 is a tissue-specific R-spondin mimetic designed to treat severe liver diseases by enhancing regenerative processes in the liver. Meanwhile, SZN-1326 is a bi-specific full-length human antibody that modulates Wnt signaling directly in target tissues. It works by binding to specific Frizzled and LRP receptors expressed in intestinal crypts, offering potential therapeutic benefits for diseases affecting the gastrointestinal tract.
The company’s approach centers on harnessing the regenerative potential of the Wnt pathway to develop targeted therapies with applications across multiple disease areas. By focusing on tissue-specific mechanisms, Surrozen aims to create treatments that are both effective and precise, minimizing off-target effects and enhancing patient outcomes.
Founded in 2015 and headquartered in South San Francisco, California, Surrozen, Inc. is at the forefront of biotechnological innovation. The company's commitment to advancing regenerative medicine through cutting-edge research and development underscores its role as a leader in the biotechnology sector, striving to address unmet medical needs with its novel therapeutic approaches.
|
